The purpose of this research study is to measure how well and how safe a drug called levosimendan (ODM-109) is in treating patients with ALS (amyotrophic lateral sclerosis). This will be done by measuring breathing function.
One of the symptoms of ALS is deterioration of upper and lower motor neurons in the nervous system with subsequent decline in muscle strength, including those muscles important for breathing.
During the course of study, staff will also ask questions about your health status, and safety will be followed by blood tests, medical examinations and documenting how much care you need for your ALS.
We are now recruiting for this study and are interested in hearing from people who:
- Have had symptoms of ALS/MND between 12-48 months
- Are able to swallow tablets
- Are not using any form of non-invasive ventilation
- Are able to commit to 12 visits to the Perron Institute over 48 weeks